100
Participants
Start Date
November 30, 2006
Study Completion Date
October 31, 2007
Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)
CHU Hôpital Salvator, Marseille
CHU Rangueil, Toulouse
Hôpital Pontchaillou, Rennes
Hôtel Dieu, Nantes
Hôpital Claude Huriez, Lille
CHU Hôpital Gabriel Montpied, Clermont-Ferrand
Hôpital Edouard Herriot, Lyon
Hôpital du Val de Grace, Paris
Centre Hospitalier Saint Louis, Paris
Hôpital Cochin, Paris
Hôpital Bichat, Paris
CHU Hôpital de la Miletrie, Poitiers
ULB Erasme, Brussels
Academisch Ziekenhuis Vrije Universiteit Brussel, Brussels
UCL St Luc, Brussels
Universitair Ziekenhuis Antwerpen, Edegem
UZ Gasthuisberg, Leuven
Olega Hublarova arsta prakse urologija, Daugavpils
Latvijas Onkologijas centre, Riga
Paula Stradina Kliniska Universitates slimnica, Riga
Kauno Medicinos Universitteto Klinikos, Kaunas
UAB 'Vilniaus onkourologijos-ginekologijos klinika, Vilnius
Vilniaus universiteto, Vilnius
Swietokrzyskie Centrum Onkologii, Kielce
NZOZ Specjalista Sp, z.o.o., Kutno
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warsaw
Akademicki Szpital Kliniczny, Wroclaw
Hospital Gregorio Maranon, Madrid
Ivano Frankovsk State Medical University, Ivano-Frankivsk
Scientific Research Institute of Urology, Kiev
Aberdeen Royal Infirmary, Aberdeen
Lead Sponsor
Ipsen
INDUSTRY